Daily investing analysis.

Korea holds the top Pixie Rank for the fifth consecutive week, now pricing at 17.8× earnings with a 124 basis-point spread to Treasuries, while homebuilders and regional banks offer the widest...

FCF yields above 4% plus payout ratios below 65% flag companies with cash flow headroom, and this week the screen is stacked with pharma, energy, and defense names doing both while trading at...

The utility screen returns eight names, but only one lives outside oil and gas: First Solar holds rank #5 with a 31% drawdown, 5.6% FCF yield, and a 24% analyst upside target while insider net...

The setup this week puts banks, energy, and biotech on the same list because the numbers converge: double-digit earnings yields, below-book or single-digit P/Es, and six-month insider dollar flows...

Korea keeps the top slot for a fourth straight week, now trading at 17.8× earnings with an earnings yield 132 basis points above Treasuries, while FRDM and AVEM show emerging-market stocks can be...

FCF yields above 4.5% with dividend cover above 2× is the delta that separates headline yield from cash reality, and this week the screen is stacked with pharma and gold names doing both. NVS...

This gas-heavy utility screen pairs 49% and 60% year-over-year revenue growth with 9–10% FCF yields on CNX and EQT, plus $5.3–$7.7M insider adds across eight names that mix Appalachia gas, majors, refining, and one solar tilt.

The value screen lines up regional banks, gas, solar, gold, biotech, refiners, and Korea in one pass: 8–10% FCF yields on BANC and CNX, a solar OEM down a third with 30% upside to targets, and an 80% ROIC biotech still priced like a cyclical.

ETFriday is a spread and multiple story: Korea at 18× with a 560 bp yield spread, EM sleeves at 13–16× with 610–780 bp spreads, regional banks at 12× with 810 bp, and Japan hedged at 15× while homebuilders sit 16% off highs into spring selling season.

Dividend Wednesday is about cash first: NVS at a 5.3% FCF yield with a 65% payout, BIIB at 7.5% FCF with 55% insider buying, T at a 10.9% FCF yield, and defense at GD where payout sits on top of 10% revenue growth and still room to redeploy cash.

Seven gas names plus FSLR: CNX leads with a 9.8% FCF yield on 49% revenue growth, EQT matches 60% growth with an 8% FCF yield, and EOG brings 15% ROIC with 28× interest coverage while insiders stay net buyers across the list.

The value screen is not about index mood; it is about eight names clustered at 0.94× book to 15× earnings with 7–10% FCF yields, 10–29% drawdowns, and three tickers still printing net insider buys after six months.

EWY still scores 10/10 at 17.8× with a 132 bp spread, FRDM adds a governance-screened EM sleeve at 177 bp, and banks land with 12–13× multiples and 360–377 bp spreads while homebuilders and clean power sit mid-teens on 14–16% drawdowns.

Nine Phase 3 programs at IDEAYA, eleven at Ionis, and twenty-two at Incyte headline this screen, with Viking running dual Phase 3 obesity studies, Revolution Medicines advancing KRAS programs, and IDEAYA enrolling its first IDE574 patient.

Breadth improved enough that sentiment gauges like Fear and Greed printed near 29, but the durable story is still cash: 5–7% FCF yields on NVS and peers, director buys stacking at defense and biotech, and payout cover that leaves room if volatility returns.

Eight energy-plus-solar names: CNX pairs 49% revenue growth with a 9.5% FCF yield at a 9.97 multiple, EQT adds 60% growth with $5.6M insider adds, and FSLR brings 17.5% ROIC on a 33% drawdown while majors show double-digit coverage and seven-figure insider lines.

Regional banks meet gas, solar, and biotech in one value pass: BANC at 0.91× book with an 8.6% FCF yield, CNX on 9.8% earnings yield with 49% revenue growth, EXEL at a 7.4% FCF yield with an 80% insider buy ratio, and FSLR down 31% with a 3.7 GW U.S. expansion headline.

Korea stays at 10/10 with a 131 bp spread on a 14% drawdown, FRDM adds a 177 bp EM governance sleeve at 16×, XHB offers a 6.7% earnings yield on builders 16% off highs, and banks plus clean power round out spreads from 13 bp up to the 240s on cyclicals.

Gene editors and platforms lead: BEAM shows 108% upside with NEJM-backed sickle data, CRSP trades at 71% upside with a 69-month runway, REGN prints 16% ROIC with Dupixent label expansion in Japan, and TWST adds bispecific discovery with 20% revenue growth.

NEM screens a 6.2% FCF yield with 6.5× payout cover, BIIB adds a 7.3% FCF yield with 55% insider buying, NUE pays a 1.3% dividend with 6.5% five-year growth and $5M insider adds, and COP ties integrated energy cash flow to still-wide commodity spreads.

Seven producers plus FSLR: CNX scores 9.5/10 with 11% ROIC and a 9.4% FCF yield at 10× earnings, DVN adds 8.7% FCF with 13.7% ROIC near cycle highs, and EQT still prints 60% revenue growth with $5.6M insider adds.

EBS trades at an 11% earnings yield after a 41% drawdown, FSLR pairs 24% revenue growth with 22% ROIC on a 29% pullback, and EXEL still shows a 6.7% earnings yield with 68.5% ROIC while eight names average a 24% drawdown and 8.2% earnings yield.

Fear and Greed touched 10/100 at the lows of this stretch, and ETF math responded: EWY at a 120 bp spread, ECH at 280 bp on copper beta, and KRE plus KBE near 350–360 bp spreads with 14–16% drawdowns off highs.

ARDX still leads with a 90% gross margin and 170% upside to targets, BEAM adds 120% revenue growth with a 43-month runway, and CRSP sits on 69 months of cash with 64% upside while pre-commercial names trade 30–50% off highs.

NEM runs a 37% ROIC with net cash and $5M insider adds, NUE and STLD show steel insiders buying into 12–14% ROIC names, and BIIB prints a 7.3% FCF yield with 55% insider buying on LEQEMBI-led cash conversion.

Only three names pass this tight screen: CNX at a 9.8% earnings yield with 48.9% revenue growth, DVN at 9.3% earnings yield with 17.4% ROIC, and EOG with 18.6% ROIC and 28× interest coverage while all three still show net insider buying.

Three names only: EBS at 8.98× earnings with an 11% earnings yield after a 41% drawdown, FSLR at 14× with 22% ROIC and 24% revenue growth off a 29% peak-to-trough slide, and NEM with 37% ROIC and 21% revenue growth plus net insider buys.

EWY scores 9.0/10 with a 126 bp spread at a 14% drawdown, ECH widens to 284 bp on Chile copper beta, and KBE prints a 356 bp spread at 12.6× earnings while Korea headlines highlight a $350B U.S. investment push and memory restock chatter.

Three clinical franchises: ARDX pairs 22% revenue growth with a 90% gross margin and $6M insider buys, BEAM adds $10M insider tickets on 120% revenue growth, and CRSP holds 69 months of runway with 64% upside despite flat six-month insider flow.

Fear and Greed touched 20/100 during this stretch, and dividend investors responded with steel and gold insider tickets plus a rare Broadcom buy cluster while payout cover stayed the north star.